YENOM · Market Intelligence & Trading

Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.

finance.yahoo.com23 mar 2026, 8:20 p.m.POSITIVO

Dow finishes higher as markets cheer potential Strait of Hormuz reopening

Dow finishes higher as markets cheer potential Strait of Hormuz reopening Proactive uses images sourced from Shutterstock 4:15pm: Broad market rally Stocks rallied to close higher on Monday, as easing geopolitical tensions and a sharp drop…

AAPL AGNPF CCL CHWY CL.COMM

Fuente original ↗Analizar →

seekingalpha.com15 oct 2025, 11:15 a.m.POSITIVO

Algernon Pharmaceuticals changes name to Algernon Health

Algernon Pharmaceuticals (OTCQB:AGNPF [https://seekingalpha.com/symbol/AGNPF]) announced [https://seekingalpha.com/pr/20266269-algernon-pharmaceuticals-completes-name-change-to-algernon-health] name change to Algernon Health. The company’s…

AGNPF

Fuente original ↗Analizar →

globenewswire.com30 nov 2023, 12:00 p.m.POSITIVO

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD

VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company, is pleased…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com22 nov 2023, 12:00 p.m.POSITIVO

Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

VANCOUVER, British Columbia, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is please…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com8 nov 2023, 12:00 p.m.POSITIVO

Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast

VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announ…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com6 sep 2023, 11:00 a.m.POSITIVO

Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH

VANCOUVER, British Columbia, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is pleased to ann…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com8 ago 2023, 11:00 a.m.POSITIVO

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is plea…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com14 jul 2023, 10:00 p.m.POSITIVO

Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement

VANCOUVER, British Columbia, July 14, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”), a Canadian clinical stage pharmaceutical development company, announces…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com27 jun 2023, 11:00 a.m.POSITIVO

Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program

VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is pleased to anno…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com6 jun 2023, 11:00 a.m.NEGATIVO

Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference

VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company is pleased…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com5 jun 2023, 11:00 a.m.POSITIVO

Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies

VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is plea…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com31 may 2023, 11:19 a.m.POSITIVO

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD

Vancouver, British Columbia, May 31, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to annou…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com5 may 2023, 9:00 p.m.POSITIVO

Algernon Pharmaceuticals Announces Closing of Rights Offering

VANCOUVER, British Columbia, May 05, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces th…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com20 abr 2023, 11:00 a.m.POSITIVO

Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time

VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is reminding its…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com17 abr 2023, 11:00 a.m.POSITIVO

Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent Application

VANCOUVER, British Columbia, April 17, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is pleased to ann…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com4 abr 2023, 11:00 a.m.POSITIVO

Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study

VANCOUVER, British Columbia, April 04, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is ple…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com3 abr 2023, 11:00 a.m.POSITIVO

Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10M

VANCOUVER, British Columbia, April 03, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is ple…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com21 mar 2023, 11:00 a.m.POSITIVO

Algernon Pharmaceuticals Announces Launch of Rights Offering

VANCOUVER, British Columbia, March 21, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com2 mar 2023, 1:00 p.m.POSITIVO

Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board

VANCOUVER, British Columbia, March 02, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to ann…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com1 mar 2023, 1:45 a.m.POSITIVO

Algernon Pharmaceuticals Announces 4 for 1 Forward Share Split

VANCOUVER, British Columbia, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company announces that effect…

AGN-CN.CN AGN.CN AGNPF AGW.F AGW0-F.F

Fuente original ↗Analizar →

globenewswire.com21 feb 2023, 12:00 p.m.POSITIVO

Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor

VANCOUVER, British Columbia, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to annou…

AGN-CN.CN AGN.CN AGNPF AGW.F AGW0-F.F

Fuente original ↗Analizar →

globenewswire.com16 feb 2023, 12:00 p.m.POSITIVO

Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase

VANCOUVER, British Columbia, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is plea…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com17 ene 2023, 12:00 p.m.POSITIVO

Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

VANCOUVER, British Columbia, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is plea…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com11 ene 2023, 12:00 p.m.POSITIVO

Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

VANCOUVER, British Columbia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is plea…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com9 ene 2023, 12:00 p.m.POSITIVO

Algernon Pharmaceuticals Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil

VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is plea…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com3 ene 2023, 12:00 p.m.POSITIVO

Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering

VANCOUVER, British Columbia, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is plea…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com5 dic 2022, 12:00 p.m.POSITIVO

Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

VANCOUVER, British Columbia, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is please…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com16 nov 2022, 12:00 p.m.POSITIVO

Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study

VANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is please…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com24 oct 2022, 11:00 a.m.POSITIVO

Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study

VANCOUVER, British Columbia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announ…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com14 oct 2022, 11:00 a.m.POSITIVO

Algernon Pharmaceuticals Announces Dr. Rick Strassman author of “DMT: The Spirit Molecule” to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference

VANCOUVER, British Columbia, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com21 sep 2022, 11:00 a.m.POSITIVO

Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian Research Program

VANCOUVER, British Columbia, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a Canadian clinical stage pharmaceutical development company, is please…

AGN-CN.CN AGN.CN AGNPF AGW.F AGW0-F.F

Fuente original ↗Analizar →

globenewswire.com19 sep 2022, 11:00 a.m.POSITIVO

Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF

VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to annou…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com12 sep 2022, 11:00 a.m.POSITIVO

Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study

VANCOUVER, British Columbia, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to annou…

AGN-CN.CN AGN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com8 sep 2022, 11:00 a.m.POSITIVO

Algernon Pharmaceuticals Secures Lead Sponsorship of 2022 Wonderland Psychedelic Conference in Miami

VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is please…

AGN-CN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com1 sep 2022, 11:00 a.m.POSITIVO

Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

VANCOUVER, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is please…

AGN-CN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →

globenewswire.com23 ago 2022, 11:15 a.m.POSITIVO

Algernon Pharmaceuticals’ Largest Shareholder AlphaNorth Asset Management Increases Ownership Position

VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to announce that its largest shareholder, AlphaNorth Asset Ma…

AGN-CN.CN AGNPF AGW0-F.F AGW0.F

Fuente original ↗Analizar →